Quarterly ResultMay 7, 2026, 04:24 PM
Arcturus Q1 Revenue Down 93% to $2.1M; Net Loss Widens to $27.0M
AI Summary
Arcturus Therapeutics reported a significant decline in its first quarter 2026 financial results, with total revenue plummeting 93% to $2.1 million compared to $29.4 million in the prior year. The company's net loss widened to $27.0 million, or $0.95 per share, from a net loss of $14.1 million, or $0.52 per share, in Q1 2025. This was primarily driven by a sharp decrease in collaboration revenue. As of March 31, 2026, cash and cash equivalents stood at $211.4 million.
Key Highlights
- Total revenue decreased 93% to $2.1 million in Q1 2026 from $29.4 million in Q1 2025.
- Net loss widened to $27.0 million ($0.95 per share) in Q1 2026 from $14.1 million ($0.52 per share) in Q1 2025.
- Collaboration revenue fell 97.6% to $0.6 million in Q1 2026 from $25.5 million in Q1 2025.
- Research and development expenses decreased 38% to $21.5 million in Q1 2026.
- Net cash used in operating activities improved to $19.4 million in Q1 2026 from $35.1 million in Q1 2025.
- Cash and cash equivalents were $211.4 million as of March 31, 2026.
- LUNAR-OTC R&D expenses increased to $2.7 million in Q1 2026 from $1.6 million in Q1 2025.